Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapcabtagene Autoleucel in Severe Refractory Idiopathic Inflammatory Myopathies
NCT06665256Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Dec 2024
- Primary completion
- Mar 2029
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 15
01
Overview
A Phase 2 trial of rapcabtagene autoleucel in idiopathic inflammatory myopathies (IIM), sponsored by Novartis. Started Dec 2024; status: active, not recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
idiopathic inflammatory myopathies (IIM)
Beyond the preview
Go deeper on NCT06665256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06665256.